Objective: To evaluate the efficacy and safety of AbobotulinumtoxinA (ABO) dose escalation in correction moderate-to-severe glabellar lines. Design: Phase 2, 36-week, multicenter, randomized, dose-ranging, double-blind, placebo-controlled study. Methods: Adults with lines received a single ABO treatment, dosed at 50, 75, 100, or 125 U, placebo. Primary endpoint was week 4 composite ≥2-grade res...